MY155029A - Peptide vaccines for cancers expressing tumor-associated antigens - Google Patents
Peptide vaccines for cancers expressing tumor-associated antigensInfo
- Publication number
- MY155029A MY155029A MYPI20093446A MYPI20093446A MY155029A MY 155029 A MY155029 A MY 155029A MY PI20093446 A MYPI20093446 A MY PI20093446A MY PI20093446 A MYPI20093446 A MY PI20093446A MY 155029 A MY155029 A MY 155029A
- Authority
- MY
- Malaysia
- Prior art keywords
- peptides
- present
- associated antigens
- expressing tumor
- peptide vaccines
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 150000001413 amino acids Chemical group 0.000 abstract 3
- 102100024153 Cadherin-15 Human genes 0.000 abstract 1
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 abstract 1
- 101150078651 Epha4 gene Proteins 0.000 abstract 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 abstract 1
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 abstract 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 abstract 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 abstract 1
- 101000839066 Homo sapiens Hypoxia-inducible lipid droplet-associated protein Proteins 0.000 abstract 1
- 101001054725 Homo sapiens Inhibin beta B chain Proteins 0.000 abstract 1
- 101001027621 Homo sapiens Kinesin-like protein KIF20A Proteins 0.000 abstract 1
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 abstract 1
- 101000817237 Homo sapiens Protein ECT2 Proteins 0.000 abstract 1
- 102100028891 Hypoxia-inducible lipid droplet-associated protein Human genes 0.000 abstract 1
- 102100027003 Inhibin beta B chain Human genes 0.000 abstract 1
- 102100037694 Kinesin-like protein KIF20A Human genes 0.000 abstract 1
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 abstract 1
- 102100040437 Protein ECT2 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/422—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90294907P | 2007-02-21 | 2007-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY155029A true MY155029A (en) | 2015-08-28 |
Family
ID=39709837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20093446A MY155029A (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
| MYPI2012004306A MY173379A (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012004306A MY173379A (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
Country Status (27)
| Country | Link |
|---|---|
| EP (20) | EP2476693B1 (enExample) |
| JP (6) | JP5239103B2 (enExample) |
| KR (8) | KR20150116463A (enExample) |
| CN (4) | CN104292299B (enExample) |
| AR (1) | AR068302A1 (enExample) |
| AU (1) | AU2008218463B2 (enExample) |
| BR (1) | BRPI0808421B1 (enExample) |
| CA (3) | CA2992074C (enExample) |
| CO (1) | CO6190536A2 (enExample) |
| CY (2) | CY1114590T1 (enExample) |
| DK (3) | DK2465864T3 (enExample) |
| ES (6) | ES2541863T3 (enExample) |
| HR (3) | HRP20131044T1 (enExample) |
| IL (10) | IL200478A (enExample) |
| MX (4) | MX337456B (enExample) |
| MY (2) | MY155029A (enExample) |
| NZ (4) | NZ591704A (enExample) |
| PH (1) | PH12014501642A1 (enExample) |
| PL (3) | PL2121731T3 (enExample) |
| PT (2) | PT2465864E (enExample) |
| RU (1) | RU2464275C2 (enExample) |
| SG (3) | SG10201506589WA (enExample) |
| SI (3) | SI2465864T1 (enExample) |
| TW (5) | TWI494319B (enExample) |
| UA (1) | UA100372C2 (enExample) |
| WO (1) | WO2008102557A1 (enExample) |
| ZA (1) | ZA200905881B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005019475A2 (en) | 2003-08-20 | 2005-03-03 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
| CN104356225B (zh) * | 2007-08-20 | 2018-02-13 | 肿瘤疗法科学股份有限公司 | Cdh3 肽以及含有cdh3 肽的药剂 |
| CA2729403A1 (en) | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| TWI543767B (zh) | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| CA2741399C (en) | 2008-10-22 | 2016-10-11 | Oncotherapy Science, Inc. | Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| TWI539160B (zh) * | 2008-12-05 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| CN102333867B (zh) * | 2008-12-24 | 2015-01-14 | 肿瘤疗法科学股份有限公司 | C1orf59肽及包含它的疫苗 |
| TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
| EP3450459B1 (en) | 2009-12-28 | 2021-05-26 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
| EP2547359B1 (en) | 2010-03-15 | 2016-03-09 | The Board of Trustees of the University of Illionis | Inhibitors of beta integrin-g protein alpha subunit binding interactions |
| TW201627003A (zh) * | 2010-04-02 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｅｃｔ２胜肽及含此胜肽之疫苗 |
| BR112013013158B1 (pt) | 2010-12-02 | 2020-04-28 | Oncotherapy Science Inc | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso |
| JP6820653B2 (ja) * | 2011-12-14 | 2021-01-27 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
| JP6159996B2 (ja) * | 2012-03-09 | 2017-07-12 | 株式会社富士薬品 | ペプチドを含む医薬組成物 |
| EP2872530A4 (en) | 2012-07-10 | 2016-04-06 | Oncotherapy Science Inc | KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME |
| WO2014010232A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Ly6k epitope peptides for th1 cells and vaccines containing the same |
| WO2014034754A1 (ja) | 2012-08-31 | 2014-03-06 | 塩野義製薬株式会社 | Psf1由来ペプチド |
| AU2013317194B2 (en) * | 2012-09-11 | 2018-07-12 | Oncotherapy Science, Inc. | UBE2T peptides and vaccines containing the same |
| WO2014141652A1 (en) * | 2013-03-11 | 2014-09-18 | Oncotherapy Science, Inc. | Smyd3 peptides and vaccines containing the same |
| TWI658049B (zh) * | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| AU2014288127A1 (en) * | 2013-07-12 | 2016-02-18 | Sapporo Medical University | Tumor antigen peptide |
| JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
| US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| EP3178837B1 (en) * | 2014-08-04 | 2021-01-13 | Oncotherapy Science, Inc. | Urlc10-derived peptide and vaccine containing same |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CN104975082B (zh) * | 2015-06-05 | 2018-11-02 | 复旦大学附属肿瘤医院 | 一组用于评估肺癌预后的基因及其应用 |
| KR20180129899A (ko) * | 2016-03-31 | 2018-12-05 | 네온 테라퓨틱스, 인크. | 신생항원 및 이것의 사용 방법 |
| WO2018090257A1 (zh) * | 2016-11-16 | 2018-05-24 | 深圳华大基因研究院 | 多肽及其应用 |
| EP4029494B1 (en) | 2017-01-25 | 2025-09-24 | OSE Immunotherapeutics | Method for manufacturing a stable emulsion for peptide delivery |
| EP3601539A4 (en) * | 2017-03-28 | 2021-01-13 | Zhenglun Zhu | METHODS OF TREATING NEOPLASIC DISEASES |
| KR102190890B1 (ko) * | 2017-08-10 | 2020-12-15 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| SG11202007750PA (en) * | 2018-02-15 | 2020-09-29 | National Univ Corporation Asahikawa Medical Univ | Cancer antigen peptide |
| KR102335916B1 (ko) * | 2019-04-22 | 2021-12-08 | 한국과학기술연구원 | 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| CN113117055A (zh) * | 2019-12-31 | 2021-07-16 | 上海细胞治疗集团有限公司 | 一种特异性结合hla-a24分型的多肽组合物及应用 |
| CN117143206B (zh) * | 2023-08-03 | 2024-09-03 | 华南农业大学 | Alv-j mhc-b21限制性表位肽及其筛选方法和应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| NZ231899A (en) * | 1985-10-03 | 1991-07-26 | Genentech Inc | Human or porcine inhibin peptide compositions and dna encoding them |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| IL103928A0 (en) * | 1991-12-11 | 1993-04-04 | American Home Prod | Expression of specific immunogens using viral antigens |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| JPH09512167A (ja) * | 1994-04-15 | 1997-12-09 | アムジエン・インコーポレーテツド | Ｈｅｋ５、ｈｅｋ７、ｈｅｋ８、ｈｅｋ１１、新規なｅｐｈ様受容体タンパク質チロシンキナーゼ |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| DE69635895D1 (de) | 1995-08-03 | 2006-05-04 | Rijksuniversiteit Te Leiden Le | Antigen presentierende bläschen, die von zellen ableiten |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| AU6795898A (en) * | 1997-04-04 | 1998-10-30 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US20020102542A1 (en) * | 1997-10-07 | 2002-08-01 | Daikichi Fukushima | Polypeptide, cdna encoding the polypeptide, and use of the both |
| US20070014787A1 (en) * | 1998-07-15 | 2007-01-18 | Human Genome Sciences, Inc. | 71 human secreted proteins |
| AU1220001A (en) * | 1999-10-20 | 2001-04-30 | Zymogenetics Inc. | Novel proteins and polynucleotides encoding them |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| US20030013649A1 (en) * | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| CN1469926A (zh) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
| AU2001277172A1 (en) | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-trans protein and related reagents and methods of use thereof |
| US6830885B1 (en) * | 2000-08-18 | 2004-12-14 | Phenogene Therapeutiques Inc. | Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature |
| US20090062512A1 (en) * | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| CN100400099C (zh) * | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
| US20040236091A1 (en) * | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| EP1463928A2 (en) | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| WO2002102235A2 (en) * | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| EP1487857A4 (en) * | 2002-03-07 | 2006-08-09 | Ludwig Inst Cancer Res | BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003300680A1 (en) * | 2002-12-10 | 2004-07-09 | Centre National De La Recherche Scientifique Cnrs | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
| AU2003297318A1 (en) * | 2002-12-20 | 2004-07-22 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
| TWI324608B (en) * | 2003-02-28 | 2010-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colorectal cancers |
| US20050100933A1 (en) * | 2003-06-18 | 2005-05-12 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2005019475A2 (en) * | 2003-08-20 | 2005-03-03 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
| WO2005083086A2 (en) * | 2004-02-27 | 2005-09-09 | Oncotherapy Science, Inc. | Epha4 as therapeutic target of prc and pdaca |
| US8193332B2 (en) * | 2004-04-09 | 2012-06-05 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| CA2566506A1 (en) * | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
| US20090075832A1 (en) * | 2005-02-24 | 2009-03-19 | Cemines, Inc | Compositions and Methods for Classifying Biological Samples |
| EP2325306B1 (en) * | 2005-02-25 | 2014-02-12 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides |
| CN100348614C (zh) * | 2005-06-03 | 2007-11-14 | 北京大学 | 一种肝癌－睾丸特异性抗原蛋白质和抗原肽 |
| ES2373055T3 (es) * | 2005-08-09 | 2012-01-31 | Oncotherapy Science, Inc. | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. |
| JP4803460B2 (ja) * | 2005-08-09 | 2011-10-26 | 学校法人 久留米大学 | Ｈｌａ−ａ２４分子結合性扁平上皮癌抗原由来ペプチド |
| US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
| WO2007064743A2 (en) * | 2005-11-30 | 2007-06-07 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| CA2648322C (en) * | 2006-04-10 | 2017-11-28 | Genentech, Inc. | Disheveled pdz modulators |
| EP2030984B1 (en) * | 2006-06-16 | 2011-05-11 | Onco Therapy Science, Inc. | Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same |
| US20090081659A1 (en) * | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1983003A3 (en) * | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| CN104356225B (zh) * | 2007-08-20 | 2018-02-13 | 肿瘤疗法科学股份有限公司 | Cdh3 肽以及含有cdh3 肽的药剂 |
| EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| TWI543767B (zh) * | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| US20120264634A1 (en) * | 2009-09-29 | 2012-10-18 | Protagen Aktiengesellschaft | Marker Sequences for Pancreatic Cancer Diseases, Pancreatic Carcinoma and Use Thereof |
-
2008
- 2008-02-18 TW TW103114624A patent/TWI494319B/zh not_active IP Right Cessation
- 2008-02-18 TW TW097105594A patent/TWI438207B/zh not_active IP Right Cessation
- 2008-02-18 TW TW104120673A patent/TWI596109B/zh not_active IP Right Cessation
- 2008-02-18 TW TW105108412A patent/TWI615403B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103107156A patent/TWI610939B/zh active
- 2008-02-21 JP JP2009534784A patent/JP5239103B2/ja active Active
- 2008-02-21 AR ARP080100718A patent/AR068302A1/es unknown
- 2008-02-21 MY MYPI20093446A patent/MY155029A/en unknown
- 2008-02-21 SI SI200831332T patent/SI2465864T1/sl unknown
- 2008-02-21 EP EP12151714.8A patent/EP2476693B1/en active Active
- 2008-02-21 EP EP12175488.1A patent/EP2583976A3/en not_active Withdrawn
- 2008-02-21 EP EP12151722.1A patent/EP2465867B1/en active Active
- 2008-02-21 EP EP12151719.7A patent/EP2465865B1/en not_active Not-in-force
- 2008-02-21 PL PL08710443T patent/PL2121731T3/pl unknown
- 2008-02-21 PL PL12151717T patent/PL2476694T3/pl unknown
- 2008-02-21 EP EP12175487.3A patent/EP2573110A3/en not_active Withdrawn
- 2008-02-21 EP EP12151711.4A patent/EP2465864B1/en not_active Not-in-force
- 2008-02-21 SI SI200831368T patent/SI2476694T1/sl unknown
- 2008-02-21 EP EP12175481.6A patent/EP2570428A3/en not_active Withdrawn
- 2008-02-21 WO PCT/JP2008/000290 patent/WO2008102557A1/en not_active Ceased
- 2008-02-21 PT PT121517114T patent/PT2465864E/pt unknown
- 2008-02-21 NZ NZ591704A patent/NZ591704A/xx not_active IP Right Cessation
- 2008-02-21 NZ NZ579768A patent/NZ579768A/en not_active IP Right Cessation
- 2008-02-21 CA CA2992074A patent/CA2992074C/en active Active
- 2008-02-21 KR KR1020157026286A patent/KR20150116463A/ko not_active Abandoned
- 2008-02-21 EP EP12175478A patent/EP2565203A1/en not_active Withdrawn
- 2008-02-21 EP EP12175482.4A patent/EP2570429A3/en not_active Withdrawn
- 2008-02-21 KR KR1020147026728A patent/KR101543623B1/ko not_active Expired - Fee Related
- 2008-02-21 CA CA2919248A patent/CA2919248A1/en not_active Abandoned
- 2008-02-21 MX MX2013009905A patent/MX337456B/es unknown
- 2008-02-21 CN CN201410449753.0A patent/CN104292299B/zh active Active
- 2008-02-21 KR KR1020157013656A patent/KR101644871B1/ko not_active Expired - Fee Related
- 2008-02-21 NZ NZ602122A patent/NZ602122A/en not_active IP Right Cessation
- 2008-02-21 ES ES12151705.6T patent/ES2541863T3/es active Active
- 2008-02-21 ES ES12151711.4T patent/ES2527397T3/es active Active
- 2008-02-21 HR HRP20131044AT patent/HRP20131044T1/hr unknown
- 2008-02-21 ES ES08710443T patent/ES2435194T3/es active Active
- 2008-02-21 ES ES12151714.8T patent/ES2532708T3/es active Active
- 2008-02-21 EP EP12175479.0A patent/EP2573109A3/en not_active Withdrawn
- 2008-02-21 SG SG10201506589WA patent/SG10201506589WA/en unknown
- 2008-02-21 EP EP12175490.7A patent/EP2574623A3/en not_active Withdrawn
- 2008-02-21 MX MX2013009906A patent/MX337417B/es unknown
- 2008-02-21 MY MYPI2012004306A patent/MY173379A/en unknown
- 2008-02-21 MX MX2009009022A patent/MX2009009022A/es active IP Right Grant
- 2008-02-21 EP EP12175480.8A patent/EP2567971A3/en not_active Withdrawn
- 2008-02-21 KR KR1020147026715A patent/KR101540000B1/ko not_active Expired - Fee Related
- 2008-02-21 EP EP12151705.6A patent/EP2476692B1/en not_active Not-in-force
- 2008-02-21 CN CN201210352621.7A patent/CN102863514B/zh active Active
- 2008-02-21 NZ NZ602119A patent/NZ602119A/en not_active IP Right Cessation
- 2008-02-21 AU AU2008218463A patent/AU2008218463B2/en not_active Ceased
- 2008-02-21 KR KR1020097019583A patent/KR101511134B1/ko not_active Expired - Fee Related
- 2008-02-21 UA UAA200909469A patent/UA100372C2/ru unknown
- 2008-02-21 ES ES12151722.1T patent/ES2540893T3/es active Active
- 2008-02-21 SI SI200831053T patent/SI2121731T1/sl unknown
- 2008-02-21 MX MX2016002567A patent/MX359680B/es unknown
- 2008-02-21 EP EP08710443.6A patent/EP2121731B1/en active Active
- 2008-02-21 ES ES12151717T patent/ES2530777T3/es active Active
- 2008-02-21 PT PT87104436T patent/PT2121731E/pt unknown
- 2008-02-21 CN CN200880012937.3A patent/CN101663315B/zh active Active
- 2008-02-21 DK DK12151711.4T patent/DK2465864T3/en active
- 2008-02-21 KR KR1020137004417A patent/KR101511140B1/ko active Active
- 2008-02-21 DK DK08710443.6T patent/DK2121731T3/da active
- 2008-02-21 CA CA2678755A patent/CA2678755C/en active Active
- 2008-02-21 RU RU2009135020/10A patent/RU2464275C2/ru active
- 2008-02-21 PL PL12151711T patent/PL2465864T3/pl unknown
- 2008-02-21 SG SG10201909675Q patent/SG10201909675QA/en unknown
- 2008-02-21 BR BRPI0808421-1A patent/BRPI0808421B1/pt not_active IP Right Cessation
- 2008-02-21 EP EP12151720A patent/EP2465866A3/en not_active Withdrawn
- 2008-02-21 EP EP12175484.0A patent/EP2594581A3/en not_active Withdrawn
- 2008-02-21 EP EP12151723A patent/EP2476695A3/en not_active Withdrawn
- 2008-02-21 DK DK12151717.1T patent/DK2476694T3/en active
- 2008-02-21 EP EP12151717.1A patent/EP2476694B1/en active Active
- 2008-02-21 CN CN201310183458.0A patent/CN103351423B/zh active Active
- 2008-02-21 SG SG2012012126A patent/SG179402A1/en unknown
- 2008-02-21 EP EP12175483.2A patent/EP2570430A3/en not_active Withdrawn
- 2008-02-21 KR KR1020167010159A patent/KR20160045939A/ko not_active Withdrawn
- 2008-02-21 KR KR1020157002221A patent/KR101644877B1/ko not_active Expired - Fee Related
- 2008-02-21 EP EP12175489.9A patent/EP2594582A3/en not_active Withdrawn
-
2009
- 2009-08-18 IL IL200478A patent/IL200478A/en active IP Right Grant
- 2009-08-25 ZA ZA200905881A patent/ZA200905881B/xx unknown
- 2009-09-21 CO CO09102283A patent/CO6190536A2/es not_active Application Discontinuation
-
2010
- 2010-02-02 JP JP2010021234A patent/JP5239104B2/ja active Active
-
2012
- 2012-04-04 IL IL219041A patent/IL219041A/en not_active IP Right Cessation
- 2012-04-04 IL IL219044A patent/IL219044A/en active IP Right Grant
- 2012-04-04 IL IL219043A patent/IL219043A/en not_active IP Right Cessation
- 2012-04-04 IL IL219046A patent/IL219046A/en not_active IP Right Cessation
- 2012-04-04 IL IL219047A patent/IL219047A0/en unknown
- 2012-04-04 IL IL219045A patent/IL219045A0/en unknown
- 2012-04-04 IL IL219048A patent/IL219048A/en not_active IP Right Cessation
- 2012-04-04 IL IL219042A patent/IL219042A/en not_active IP Right Cessation
- 2012-04-04 IL IL219040A patent/IL219040A/en active IP Right Grant
- 2012-11-29 JP JP2012260421A patent/JP5608953B2/ja active Active
- 2012-11-29 JP JP2012260412A patent/JP5614761B2/ja active Active
-
2013
- 2013-11-08 CY CY20131100994T patent/CY1114590T1/el unknown
-
2014
- 2014-07-17 PH PH12014501642A patent/PH12014501642A1/en unknown
- 2014-07-24 JP JP2014150295A patent/JP5874158B2/ja not_active Expired - Fee Related
- 2014-12-17 HR HRP20141233AT patent/HRP20141233T1/hr unknown
- 2014-12-18 CY CY20141101067T patent/CY1115841T1/el unknown
-
2015
- 2015-01-28 HR HRP20150108TT patent/HRP20150108T1/hr unknown
- 2015-12-25 JP JP2015252737A patent/JP2016094459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501642B1 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| EP2476697A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
| DE602007011901D1 (de) | Ptiden und zellpenetrierenden peptiden gekoppelt a | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
| WO2006090810A3 (en) | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides | |
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| MX2010005816A (es) | Epítopos de péptido de stat3. | |
| NZ592461A (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same | |
| EP4047009A3 (en) | Wdrpuh epitope peptides and vaccines containing the same | |
| ES2529713T3 (es) | Péptidos anticonceptivos derivados de veneno de araña | |
| WO2009149094A3 (en) | Cytotoxic t cell defined egfr peptide and an optimized derivative peptide | |
| TH126305A (th) | อนุพันธุ์เพพไทด์ vapeehptllteaplnpk ที่มีการกระตุ้นทางชีวภาพ |